Cargando…

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

BACKGROUND AND AIMS: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. METHODS: In this phase 3b/4, open-label, multicentre, prospective, single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubin, David T., Bradette, Marc, Gabalec, Libor, Dobru, Daniela, Márquez, Juan, Inglis, Susi, Magee, Elizabeth, Solomon, Dory, D’Haens, Geert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962361/ https://www.ncbi.nlm.nih.gov/pubmed/26908939 http://dx.doi.org/10.1093/ecco-jcc/jjw049

Ejemplares similares

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
por: Takeshima, Fuminao, et al.
Publicado: (2014)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Mesalazine-Induced Interstitial Nephritis in a Patient With Ulcerative Colitis
por: da Cunha Marques, José, et al.
Publicado: (2022)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis
por: Haasnoot, Maria L, et al.
Publicado: (2022)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
por: Tsuboi, Rumiko, et al.
Publicado: (2018)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2016)

OA07.03. Randomized, double-blind, double-dummy trial of myrrh, chamomile, coffee charcoal compared to mesalazine in maintaining remission in ulcerative colitis
por: Langhorst, J, et al.
Publicado: (2012)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
por: Arai, Yoshinori, et al.
Publicado: (2011)

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report
por: Huang, Po-Han, et al.
Publicado: (2018)

Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis
por: Pan, Chengyu, et al.
Publicado: (2022)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis
por: De Voogd, Floris, et al.
Publicado: (2021)

The effects of crocin, mesalazine and their combination in the acetic acid-induced colitis in rats
por: Faramarzpour, Amir, et al.
Publicado: (2019)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
por: Khanna, Raoul Kanav, et al.
Publicado: (2018)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_52ld4qe0qcvtmhpc9tm2risvrd